🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

68Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors

Recruitingn/aAges 18 Years - 80 YearsAllPeking University First Hospital
NCT07331532 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Tumor metastasis and invasion are the leading causes of cancer-related deaths, with over 90% of cancer patients dying from distant metastasis. Tumor cells spread to distant organs through local infiltration, hematogenous metastasis, or lymph node metastasis, complicating treatment and severely affecting the prognosis and survival rate of patients. Therefore, precise and early assessment of tumor invasion and metastasis is crucial for optimizing personalized treatment plans and improving patient survival. Currently, the detection of tumor metastasis primarily relies on imaging examinations, blood biomarkers, and histopathological analysis. Among these, 18F-FDG PET/CT plays a key role in tumor staging and distant metastasis evaluation. However, its sensitivity is low for certain tumors, such as well-differentiated hepatocellular carcinoma, colorectal cancer, and glioblastoma, and factors

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients aged 18-80 years. * Diagnosed with confirmed lung cancer. * Scheduled to undergo pathological tissue biopsy or surgical treatment within the next two months. * Able to fully comprehend and voluntarily participate in the study. * Able to provide informed consent. * Capable of cooperating independently to complete the examinations. Exclusion Criteria: * Patients with other malignancies or severe comorbidities that affect their ability to participate. * Patients unable to provide informed consent due to cognitive impairment. * Patients with contraindications to PET/CT scans or 68Ga-PFA2 administration.
💊

What it tests

  • Not listed
📍

Where

1 site
Peking university first hospital nuclear medicine
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy